Author:
Imai Yumi,Morris Margaret A.,Dobrian Anca D.,Taylor-Fishwick David A.,Nadler Jerry L.
Reference301 articles.
1. Aceves M, Duenas A, Gomez C, San Vicente E, Crespo MS, Garcia-Rodriguez C (2004) A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription. J Immunol 173:5721–5729
2. Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG (2004) Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 53:384–392
3. Akesson C, Uvebrant K, Oderup C, Lynch K, Harris RA, Lernmark A, Agardh CD, Cilio CM (2010) Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clin Exp Immunol 161:48–56
4. Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D (2012) Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes 61:2525–2533
5. Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M (2009) Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 58:138–145